BiOM® Changes Name to BionX™ - Gilde Healthcare

BiOM® Changes Name to BionX™

28. September 2015

New Name Highlights Company’s Core Competency in the Prosthetic Device Market

BEDFORD, Mass — iWalk (also known as BiOM®), a leader in the field of bionic prosthetic devices, announced today that the company has relaunched itself as BionX™ Medical Technologies, Inc. to better reflect its commitment to delivering bionic solutions that address critical unmet needs in the market. The company will unveil its new name and logo during its presentation at the Ladenburg Thalmann Healthcare Conference in New York City on Tuesday, September 29th. The corporate relaunch also reflects a series of significant company milestones, including the addition of an industry-leading executive team, market-leading product enhancements, international commercial expansion and ongoing support from reimbursement authorities such as the U.S. Department of Veterans Affairs and Workers’ Compensation payers across the U.S.

 “Our company was founded to revolutionize the prosthetic device industry by providing products, based on our bionic platform, that enable patients to have more freedom in their lives. Over the last year, we have made significant progress towards achieving this goal, having fortified our corporate organization, disciplined our commercial execution and continually expanded our IP portfolio and product pipeline,” said Dr. Charles S. Carignan, President and CEO of BionX. “Our new name helps communicate our commitment to offering bionic solutions that restore normalized limb function and improve quality of life. We are continually inspired by our patients who strive to achieve their greatest potential.”

The BiOM® Ankle, the company’s flagship product, is the only lower-limb prosthesis with powered propulsion for enhanced mobility. Only the BiOM Ankle provides power that emulates lost muscle function, control that mimics normal ankle movement and stability that automatically adjusts to any surface.

BionX is in the process of executing several key growth drivers including expanded insurance reimbursement, international commercial expansion and new product introductions.

About BionX™:

BionX is a leader in the field of prosthetic devices with their flagship product the BiOM Ankle, the only lower-limb prosthesis with powered propulsion for enhanced mobility. Privately held and headquartered in Bedford, Mass., BionX was originally founded in 2007 as iWalk by Dr. Hugh Herr, Director and Principal Investigator of the Biomechatronics Group of MIT’s Media Laboratory, and funded by leading investment firms including WFD Ventures, General Catalyst Partners, Sigma Partners, and Gilde Healthcare Partners. The company has also received funding and support from the U.S. Department of Veterans Affairs and the U.S. Army’s Telemedicine and Advanced Technology Research Center (TATRC).

About the BiOM® Ankle:

The BiOM Ankle leverages patented technology to address the limitations of current lower-limb prostheses. Only the BiOM Ankle provides power that emulates lost muscle function, control that mimics normal ankle movement and stability that automatically adjusts to any surface. Clinical studies have shown that the BiOM Ankle can help people to walk faster and farther with less energy, improve balance and stability, reduce joint forces that lead to pain and more easily climb ramps, hills and stairs.1-7

WWW.BIONXMED.COM

WWW.TRY-BIOM.COM

Gilde Healthcare company SpliceBio announces first patient dosed in Phase 1/2 ASTRA study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt disease   SpliceBio,...
13. März 2025

Gilde Healthcare participates in $65 Million financing of Microtransponder to enhance Vivistim adoption for Chronic Stroke Recovery

MicroTransponder®, Inc, today announces a $65 million Series F financing round. MicroTransponder is a fast growing commercial stage stroke company with the FDA-approved Vivistim® Paired VNS™ System. Gilde Healthcare joins the round as new investor,...
12. März 2025

Gilde Healthcare Company Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer

Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, today announces the appointment of Haseeb Ahmad as its Chief Executive Officer and member of the Board of Directors effective immediately. Haseeb...
12. März 2025